vs
KRONOS WORLDWIDE INC（KRO）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Revvity的季度营收约是KRONOS WORLDWIDE INC的1.8倍（$772.1M vs $418.3M），Revvity净利率更高（12.7% vs -19.8%，领先32.5%），Revvity同比增速更快（5.9% vs -1.1%），Revvity自由现金流更多（$161.8M vs $81.9M），过去两年Revvity的营收复合增速更高（9.0% vs -6.5%）
克罗诺斯全球（原克罗诺斯公司）是一家美国跨国企业，总部位于美国马萨诸塞州洛厄尔，专注于提供劳动力管理与人力资本管理云服务，在全球拥有超过6000名员工，是该领域知名的服务提供商。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
KRO vs RVTY — 直观对比
营收规模更大
RVTY
是对方的1.8倍
$418.3M
营收增速更快
RVTY
高出7.0%
-1.1%
净利率更高
RVTY
高出32.5%
-19.8%
自由现金流更多
RVTY
多$79.9M
$81.9M
两年增速更快
RVTY
近两年复合增速
-6.5%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $418.3M | $772.1M |
| 净利润 | $-82.8M | $98.4M |
| 毛利率 | -0.9% | — |
| 营业利润率 | -15.1% | 14.5% |
| 净利率 | -19.8% | 12.7% |
| 营收同比 | -1.1% | 5.9% |
| 净利润同比 | -527.3% | 3.9% |
| 每股收益（稀释后） | $-0.72 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收KRORVTY
| Q4 25 | $418.3M | $772.1M | ||
| Q3 25 | $456.9M | $698.9M | ||
| Q2 25 | $494.4M | $720.3M | ||
| Q1 25 | $489.8M | $664.8M | ||
| Q4 24 | $423.1M | $729.4M | ||
| Q3 24 | $484.7M | $684.0M | ||
| Q2 24 | $500.5M | $691.7M | ||
| Q1 24 | $478.8M | $649.9M |
净利润KRORVTY
| Q4 25 | $-82.8M | $98.4M | ||
| Q3 25 | $-37.0M | $46.7M | ||
| Q2 25 | $-9.2M | $53.9M | ||
| Q1 25 | $18.1M | $42.2M | ||
| Q4 24 | $-13.2M | $94.6M | ||
| Q3 24 | $71.8M | $94.4M | ||
| Q2 24 | $19.5M | $55.4M | ||
| Q1 24 | $8.1M | $26.0M |
毛利率KRORVTY
| Q4 25 | -0.9% | — | ||
| Q3 25 | 10.3% | 53.6% | ||
| Q2 25 | 12.7% | 54.5% | ||
| Q1 25 | 21.8% | 56.5% | ||
| Q4 24 | 20.4% | — | ||
| Q3 24 | 20.9% | 56.3% | ||
| Q2 24 | 20.0% | 55.7% | ||
| Q1 24 | 14.9% | 54.6% |
营业利润率KRORVTY
| Q4 25 | -15.1% | 14.5% | ||
| Q3 25 | -4.2% | 11.7% | ||
| Q2 25 | 1.5% | 12.6% | ||
| Q1 25 | 7.8% | 10.9% | ||
| Q4 24 | 6.8% | 16.3% | ||
| Q3 24 | 8.0% | 14.3% | ||
| Q2 24 | 7.2% | 12.4% | ||
| Q1 24 | 4.1% | 6.8% |
净利率KRORVTY
| Q4 25 | -19.8% | 12.7% | ||
| Q3 25 | -8.1% | 6.7% | ||
| Q2 25 | -1.9% | 7.5% | ||
| Q1 25 | 3.7% | 6.4% | ||
| Q4 24 | -3.1% | 13.0% | ||
| Q3 24 | 14.8% | 13.8% | ||
| Q2 24 | 3.9% | 8.0% | ||
| Q1 24 | 1.7% | 4.0% |
每股收益（稀释后）KRORVTY
| Q4 25 | $-0.72 | $0.86 | ||
| Q3 25 | $-0.32 | $0.40 | ||
| Q2 25 | $-0.08 | $0.46 | ||
| Q1 25 | $0.16 | $0.35 | ||
| Q4 24 | $-0.11 | $0.77 | ||
| Q3 24 | $0.62 | $0.77 | ||
| Q2 24 | $0.17 | $0.45 | ||
| Q1 24 | $0.07 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $33.2M | $919.9M |
| 总债务越低越好 | $557.4M | — |
| 股东权益账面价值 | $751.1M | $7.3B |
| 总资产 | $1.8B | $12.2B |
| 负债/权益比越低杠杆越低 | 0.74× | — |
8季度趋势，按日历期对齐
现金及短期投资KRORVTY
| Q4 25 | $33.2M | $919.9M | ||
| Q3 25 | $27.7M | $931.4M | ||
| Q2 25 | $18.9M | $991.8M | ||
| Q1 25 | $20.5M | $1.1B | ||
| Q4 24 | $106.7M | $1.2B | ||
| Q3 24 | $94.8M | $1.2B | ||
| Q2 24 | $133.8M | $2.0B | ||
| Q1 24 | $120.7M | $1.7B |
总债务KRORVTY
| Q4 25 | $557.4M | — | ||
| Q3 25 | $626.2M | — | ||
| Q2 25 | $589.3M | — | ||
| Q1 25 | $557.2M | — | ||
| Q4 24 | $507.4M | — | ||
| Q3 24 | $554.3M | — | ||
| Q2 24 | $423.7M | — | ||
| Q1 24 | $426.9M | — |
股东权益KRORVTY
| Q4 25 | $751.1M | $7.3B | ||
| Q3 25 | $804.7M | $7.4B | ||
| Q2 25 | $846.8M | $7.6B | ||
| Q1 25 | $847.0M | $7.6B | ||
| Q4 24 | $817.0M | $7.7B | ||
| Q3 24 | $847.4M | $7.9B | ||
| Q2 24 | $774.6M | $7.9B | ||
| Q1 24 | $774.4M | $7.8B |
总资产KRORVTY
| Q4 25 | $1.8B | $12.2B | ||
| Q3 25 | $1.9B | $12.1B | ||
| Q2 25 | $1.9B | $12.4B | ||
| Q1 25 | $1.9B | $12.4B | ||
| Q4 24 | $1.9B | $12.4B | ||
| Q3 24 | $1.9B | $12.8B | ||
| Q2 24 | $1.7B | $13.4B | ||
| Q1 24 | $1.7B | $13.4B |
负债/权益比KRORVTY
| Q4 25 | 0.74× | — | ||
| Q3 25 | 0.78× | — | ||
| Q2 25 | 0.70× | — | ||
| Q1 25 | 0.66× | — | ||
| Q4 24 | 0.62× | — | ||
| Q3 24 | 0.65× | — | ||
| Q2 24 | 0.55× | — | ||
| Q1 24 | 0.55× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $92.1M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $81.9M | $161.8M |
| 自由现金流率自由现金流/营收 | 19.6% | 21.0% |
| 资本支出强度资本支出/营收 | 2.4% | 2.6% |
| 现金转化率经营现金流/净利润 | — | 1.85× |
| 过去12个月自由现金流最近4个季度 | $-40.4M | $509.4M |
8季度趋势，按日历期对齐
经营现金流KRORVTY
| Q4 25 | $92.1M | $182.0M | ||
| Q3 25 | $-7.9M | $138.5M | ||
| Q2 25 | $20.7M | $134.3M | ||
| Q1 25 | $-102.4M | $128.2M | ||
| Q4 24 | $49.3M | $174.2M | ||
| Q3 24 | $28.3M | $147.9M | ||
| Q2 24 | $38.2M | $158.6M | ||
| Q1 24 | $-43.3M | $147.6M |
自由现金流KRORVTY
| Q4 25 | $81.9M | $161.8M | ||
| Q3 25 | $-17.4M | $120.0M | ||
| Q2 25 | $9.5M | $115.5M | ||
| Q1 25 | $-114.4M | $112.2M | ||
| Q4 24 | $37.0M | $149.8M | ||
| Q3 24 | $19.2M | $125.6M | ||
| Q2 24 | $34.8M | $136.6M | ||
| Q1 24 | $-48.0M | $129.7M |
自由现金流率KRORVTY
| Q4 25 | 19.6% | 21.0% | ||
| Q3 25 | -3.8% | 17.2% | ||
| Q2 25 | 1.9% | 16.0% | ||
| Q1 25 | -23.4% | 16.9% | ||
| Q4 24 | 8.7% | 20.5% | ||
| Q3 24 | 4.0% | 18.4% | ||
| Q2 24 | 7.0% | 19.7% | ||
| Q1 24 | -10.0% | 20.0% |
资本支出强度KRORVTY
| Q4 25 | 2.4% | 2.6% | ||
| Q3 25 | 2.1% | 2.6% | ||
| Q2 25 | 2.3% | 2.6% | ||
| Q1 25 | 2.4% | 2.4% | ||
| Q4 24 | 2.9% | 3.4% | ||
| Q3 24 | 1.9% | 3.3% | ||
| Q2 24 | 0.7% | 3.2% | ||
| Q1 24 | 1.0% | 2.7% |
现金转化率KRORVTY
| Q4 25 | — | 1.85× | ||
| Q3 25 | — | 2.97× | ||
| Q2 25 | — | 2.49× | ||
| Q1 25 | -5.66× | 3.03× | ||
| Q4 24 | — | 1.84× | ||
| Q3 24 | 0.39× | 1.57× | ||
| Q2 24 | 1.96× | 2.87× | ||
| Q1 24 | -5.35× | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
KRO
暂无分部数据
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
